Embed Size (px)
Citation preview
program and expand its multidisciplinary molecular imaging program.
UChicago will be the only academic medical institution in Illinois with an operational cyclotron. More info
The development of the synthesis protocols for both 18F-PSMA on Synthera® V2 have been achieved with high yields and high radiochemical and chemical purity over its entire shelf-life. The recipes are available at the IBA Library of compounds and the set of consumables ready to use will be manufactured by ABX in Q2/Q3 2017. The processes will soon be available also on the new Synthera®+ generation.
PSMA is a recognized target for prostate cancer. According to the American Cancer society, about 1 man in 7 will be diagnosed with prostate cancer during his lifetime.
There have been numerous studies based on low-molecular-weight agents with PSMA labelled with different radioisotopes. Initial studies with the second generation of 18F-labelled PSMA-1007 for imaging of prostate cancer patients have demonstrated its ability to reveal metastatic lesions that are difficult to be identified with other imaging modalities1.
Read the full press release
1. The radiopharmaceuticals cited here are
investigational drugs and can only be used under
approved clinical trials application.
SUCCESSFUL SYNTHESIS OF 18F-PSMA- 1007 ON SYNTHERA®
RADIOPHARMA SOLUTIONSNEWSLETTER N°18- SUMMER 2017
Oliver Holderbaum Head of Global Sales RPS [email protected]
Sylvain Savaria Vice President NA [email protected]
Li ChenSales Director [email protected]
Claudia Ochoa Vice President Global Chemistry Solutions [email protected]
Peter Leitner Vice President APAC [email protected]
Ambrosio Moreno Vice President LATAM [email protected]
Frederic Jodocy Vice President [email protected]
IBA RadioPharma SolutionsChemin du cyclotron, 3 1348 Louvain-la-Neuve Belgium
Tél. : +32 10 201 275 Fax : + 32 10 47 59 00 [email protected]
IBA received the acceptance test of the Cyclone®18 installed at the University of Chicago.
In 1968, UChicago was one of the first academic institutions to install a cyclotron to produce short-lived radioactive isotopes for imaging. That machine was decommissioned in 1997.
The new cyclotron will allow UChicago researchers to manufacture radioactive isotopes, which can be used to diagnose disease, predict outcomes, and assess the effects of drugs. With the ability to more easily incorporate chemistry into imaging, the university will revive its radiochemistry
A CYCLONE® KIUBE SOON AT HUS HELSINKI
IBA RadioPharma Solutions signed a contract with HUS Hospital in Helsinki for the installation of an IntegraLab® project. This project includes a Cyclone® KIUBE, Synthera® multi-tracer radiochemistry platform as well as hot cells and QC equipment. The hospital plans to produce FDG as well as various 18F compounds, 68Ga and 11C.
The combination of your technical and commercial solution widely
contributed to our decision to work with you. Procurement procedure was pretty long, but the precise and high quality answers as well as total price madethe difference between competitors. We are looking forward to a new Cyclone® KIUBE cyclotron!
Ph.D. Tomi Kauppinnen Development DirectorHUS Medical Imaging Center
CLOSER TO THE USERS
ALREADY MORE THAN 100 USERS REGISTERED FOR THE IBA USERS MEETING 2017
The 11th IBA PET Cyclone® Users Meeting is from September 17th-20th 2017 and our 5th Synthera® Users Meeting is from September 19th-21st 2017.
This bi-annual event dedicated to the IBA PET User’s community is the best opportunity to exchange, learn, discuss and share experience with other users and with us through the different workshops, roundtables and social events. We hope this contact and interaction will help to foster the strong network we have.We strongly encourage all our customers to take part in this meeting, which is a great opportunity to share ideas and experience.
More info: [email protected]
IBA’s headquarters, Louvain-la-Neuve, Belgium
IBA AROUND THE WORLD
iba-RadiopharmaSolutions.com
At IBA, we are keen on sharing our solutions with the rest of the world. Here are some events where you might have seen us…
ARAB HEALTHIn January, during the Arab Health annual meeting, IBA’s experts for the MiddleEast presented our radiopharmaceutical production solutions with the Cyclone®
KIUBE and the unique Synthera®+ family.
ROADSHOW IN CHINA
Beijing, Gwangzhou, Shanghai and all across China, the whole industry has been impressed by the production capacity of the IBA Cyclone® KIUBE and Synthera®+.
MEDDIAGNOSTICSDuring this annual healthcare meetingthe IBA Russia team was pleased toshare their expertise on the integrationof GMP radiopharmacies and to showcasethe IBA IntegraLab® solutions.
ISRSIBA RadioPharma Solutions annonced two important novelties during ISRS 2017: - The Fixed IFP™ cassette that allows Synthera®+ to be the only synthesizer compatiblewith both a disposable and non-disposable cassette systems- The successful syntheses of 18F-PSMA-1007 and 18F-DCFPYL on Synthera® platform
SNMMIWe were happy to show the real size Cyclone® KIUBE at our booth. Thanks to its compact design, it can fit into any existing cyclotron vault. The team also presented the new Synthera®+ Family with all its accessories; the IFP loader, the Synthera®+ HPLC, the Synthera® extension and the fixed IFP.
IBA RECEIVED THE ACCEPTANCE TEST OF THE CYCLONE®18 INSTALLED AT THE UNIVERSITY OF CHICAGO
IBA RECEIVED THE ACCEPTANCE TEST OF THE CYCLONE®18 INSTALLED IN YAMANASHI
The Cyclone® 18/9 installed at the University of Yamanashi succesfully passed its acceptance test . Thanks to this new cyclotron, the University hospital of Yamanashi will be able to supply a brand new PET-CT center.
The Cyclone® 18 was successfully rigged into its vault at INCART (Instituto Nacional del Cáncer Rosa Emilia Sánchez Pérez de Tavares) in Dominican Republic. This project includes a Cyclone®18, two Synthera® platform and IntegraLab®
services.
The new radiopharmacy and PET/CT center will allow the National Cancer Institute to have more reliable diagnoses and in less time, resulting in more specific treatment. This will benefit patients at the Cancer
Institute, but also provide assistance to other medical centers in the country.
WATCH THIS VIDEO OF IBA’S CYCLOTRON RIGGING AT EASTERN HEALTH’S NUCLEAR AND MOLECULAR IMAGING FACILITY
The new radiopharmacy will greatly benefit cancer patients in the province as it will allow patients to be cared for locally.
CONTINUOUS IMPROVEMENT OF OUR CUSTOMER SUPPORT
RadioPharma Solutions flying engineers from all around the world gathered in Belgium to share their experience and review the major technological concepts & good practices of RPS customer services department. The training and experience sharing allows IBA to continuously improve its customers support.
With more than 500 units installed worldwide, the Synthera® family has proven to be highly eff icient and trustworthy. Now, through its program of continuous innovation, IBA has redesigned Synthera® to meet and exceed the ever-growing customer expectations. The result is the new Synthera®+, giving radiopharma producers more capacity, more potential and more reliability.
Synthera®+ remains the most compact module on the market: up to 3 synthesizers can fit into a standard hot cell.
“Synthera®+ can be equipped with the automatic IFP Loader* (disposable production cassette dispenser) which can
stack up to 4 cassettes,” explains Neva Lazarova, Head of IBA Radiochemistry Solutions. “This allows it to perform consecutive runs of different compounds without opening the hot cell, resulting in nearly zero radiation exposure to the operator. This unique feature multiplies the capability of each module by a factor of four.”
CHEMISTRY
SUCCESSFULL RIGGING OF THE CYCLONE® 18 IN DOMINICAN REPUBLIC
T H E F I X E D I F P ™ , A N E W S Y N T H E R A ® + A C C E S S O R Y TO ENHANCE DEVELOPMENT CAPABILITIES
The Fixed IFP™ system is an optional Synthera®+ accessory which will soon be available for pilot tests. New radiotracers can be developed with the Fixed IFP™ system and, once the synthesis is well established, the IFP™ disposable cassette should be utilized for routine productions. The Fixed IFP™ increases Synthera®+ development capabilities at reduced cost and in less time since the development is performed on the Fixed IFP™ system with a direct translation to the IFP™ disposable cassette.
Synthera®+ is the only synthesizer compatible with both a disposable and non-disposable cassette systems. more info
IBA AWARD ON THE BEST SCIENTIFIC PAPER ON CHEMISTRY EQUIPMENT
Every year, IBA gives a scientific award for the best paper or abstract published in a scientific journal, proceedings of a conference using IBA equipment including cyclotron, targetry and/or chemistry.
This year’s winner is Dr. Mark H. Dornan from the University of Montreal Hospital Research Centre (CRCHUM) in Canada for his paper “Automated radiosynthesis of the 18F-fluoropropylsulfonyl derivative of TAK875, a FFA1-binding PET radiotracer for β-cell mass imaging” which was accepted for oral presentation at the 22nd International Symposium on Radiopharmaceutical Sciences 2017. Read the paper
Be the next winner: send your scientific publication to : [email protected]
CHEMISTRY
SUCCESS STORIES
SYNTHERA®+: BETTER, SMARTER, STRONGER
BETTER: multiple runs of multiple tracers for a cost effective solution
SMARTER:accessory-based for maximum flexibility
STRONGER: reliable for consistent yield and high uptime
CLOSER TO THE USERS
IBA AROUND THE WORLD
SUCCESS STORIES
